The article argues that with the 10-Year Treasury yielding 5.1%, long-term investors may consider dividend stocks over fixed-income assets, since blue chips tend to appreciate over time. It highlights Altria (MO), an S&P 500 component and a Dividend King with 57 consecutive years of dividend increases, as an example. As the largest US tobacco company, Altria faces a decline in adult smoking from over 40% in the 1960s to under 10% today, which it offsets through price increases, cost cuts, buybacks and expansion in smokeless products, targeting at least $5 billion in smoke-free revenue by 2028. The stock trades at 13 times forward earnings with a forward yield of 6%. According to the article, a $5,000 investment could generate about $300 in annual income.
Summary written by Upside AI from the original article. Read the source for full details.
Read the original on Yahoo Finance ↗
Related news
- Elon Musk may have just taken a major step toward consolidating his empire
- Microsoft Just Took Its Biggest Step Toward Independence From Nvidia
Microsoft announced Azure Maia 300, its newest in-house AI chip, and said Maia will become the primary inference system for its products, with multi-gigawatt deployments starting in 2027. Microsoft claims Maia 300 produces 40% more tokens per megawatt than leading GPU systems, though its 96-chip rack draws about 167 kilowatts versus 142 kilowatts for Nvidia's 72-GPU GB300 rack. The chip is meant to lower the cost of Microsoft's own Copilot and OpenAI services, which it does not sell as chips, while the company expects capital spending above $175 billion this calendar year and will keep leasing Nvidia chips for training. Evercore ISI estimates Maia will account for about 10% of Microsoft's AI chip spending by early 2027. All performance figures come from Microsoft and have not been tested independently, and the next checkpoint is the October 28 earnings call.
- One Analyst Said SpaceX Has "Significant Moats" and Just Put a Buy Rating on the Stock. Is He Right?
- I Just Invested $4,600 Across 3 Top Dividend Stocks. Here’s What I’m Loading Up on Right Now.
The author says they are shifting toward a more defensive portfolio due to warning signs, including the CAPE ratio at its second-highest level in history, soaring margin debt, persistent inflation, and the Fed's recent first rate hike in three years. They sold several lower-conviction holdings and invested over $4,600 in Abbott (ABT), Procter & Gamble (PG) and Paychex (PAYX). Citing Ned Davis Research and Hartford Funds data, dividend growers averaged a 10.2% annual total return over the past 50 years versus 4.2% for non-payers, with a lower average beta (0.89 vs. 1.18). The picks rest on durable cash flows and rising dividends: Abbott has raised its dividend for 54 consecutive years and yields 2.4%, P&G has 70 straight years of increases and a yield of nearly 2.8%, and Paychex yields 4.3% after a 10% hike.
- Johnson & Johnson Just Raised Its Sales Outlook Again. Here's Why the Dividend King Is Still a Buy.
Johnson & Johnson's third-quarter revenue rose 6% to $25.9 billion and adjusted EPS of $2.59 fell 7.5% year over year, both topping most analyst estimates, and the company raised its full-year 2026 operational sales growth guidance to 6.4% to 6.8%. However, MedTech revenue rose only 2.5% to $8.6 billion, short of the consensus of just over $8.7 billion, and the stock fell nearly 6% after the release; CFO Joe Wolk called the division's results 'disappointing,' and the company floated a spinoff of its DePuy Synthes orthopedics business sometime in 2027. The article notes MedTech accounts for about one-third of sales and under 20% of adjusted net income, while oncology grew more than 16% to $7.6 billion in the quarter, with J&J targeting at least $50 billion in oncology sales by 2030. It also highlights a forward dividend yield of about 2% backed by a 64-year dividend growth streak as a reason the stock may be easier to hold through volatility.
- Pfizer Just Declared Its 352nd Straight Quarterly Dividend. Is the 6% Yield Safe?
Pfizer declared a $0.43 fourth-quarter dividend, its 352nd consecutive quarterly payout, which annualizes to $1.72 per share and a 5.9% yield, well above the roughly 1% average S&P 500 yield. The article asks whether the payout is sustainable, noting Pfizer halved its dividend in 2009 but has raised it every year since 2010. Eliquis and Xeljanz lose U.S. patent exclusivity this year, and Ibrance and Xtandi follow next year, which pressures revenue. Nurtec grew 18% in the second quarter, Lorbrena 37% and Padcev 23%, and free cash flow of about $11 billion over four quarters exceeded dividend payments by more than $1 billion. The author concludes that the dividend's durability depends on whether new pipeline drugs can replace the expiring ones.
Related markets
Latest news
- Nscale in talks for $45 billion Anthropic AI deal as IPO looms
Nscale is in talks to secure a computing deal worth about $45 billion with Anthropic, according to Bloomberg News, which could strengthen the Nvidia-backed data center developer's bid for a roughly $30 billion valuation in its planned IPO. The proposed agreement would cover a second building at Nscale's Monarch campus in West Virginia, delivering 460 megawatts of capacity powered by Nvidia's Vera Rubin chips, and could be finalized within days, though terms could still change. Anthropic already has infrastructure agreements with Nscale worth as much as $44.6 billion, according to Nscale's IPO filing, and holds a right of first refusal on the campus's anticipated third building. Investors are scrutinizing AI infrastructure economics, and Nscale faces questions similar to CoreWeave's about financing, execution and converting its backlog into cash flow, since its contracts are future commitments rather than collected cash. Representatives for Nscale and Anthropic declined to comment.
- Trump says he'd meet with Putin and Xi, criticizes Zelenskyy
President Donald Trump said he would meet Russian President Vladimir Putin and Chinese President Xi Jinping to discuss ending the Ukraine war, and suggested such a meeting could happen without Zelenskyy present. He said Russia and China have done 'very little' to help Tehran, which has been accused of receiving their support in its military efforts against the U.S. Trump also criticized Zelenskyy's reaction to his decision to waive new sanctions against Russia, saying Zelenskyy 'doesn't know what he's talking about' and should have settled the war long ago. He added that 'it's time for somebody else to negotiate on behalf of Ukraine,' echoing his earlier call for Kyiv to get a new president.
- Market participants weigh in on SEC’s proposed crypto regulations
The SEC will close public comment on its “Regulation Crypto Assets” proposal, first introduced in August, on Tuesday. Over the 60-day period, the agency received about 140 comments on a proposed safe harbor that would keep token issuers from being treated as investment contracts, along with exemptions for offerings up to a set amount. The MiCA Crypto Alliance largely supported the proposed disclosure changes but asked the SEC to better define crypto-specific concepts and data structures. SkyBridge Capital founder Anthony Scaramucci also backed the rules, calling them a return to the Commission’s proper role, though he did not mention Congress’s inaction on the CLARITY Act. Some legal experts warn the rules could be overturned more easily than an act of Congress, and both the SEC and the CFTC remain understaffed at the leadership level.
- Why Lockheed Martin May Be an Underrated Stock to Buy Right Now
The article argues that Lockheed Martin (LMT) can withstand market volatility, with its stock up about 15% this year while still offering good value. In 2022, when the market fell, LMT’s total return including dividends was over 40%, compared with a negative 18% for the S&P 500, helped by its close ties to the U.S. government and strong defense spending. In the quarter ended June 28, revenue reached $20.1 billion, up 11% year over year. The stock trades at a forward P/E of about 16, below the S&P 500’s more than 19, and its dividend yields 2.6% versus the index’s roughly 1%. The company has raised its dividend for 24 consecutive years, which the article cites as a reason to hold the stock long term.
- Canadian dollar notches nearly four - week high on BoC rate hike bets
The Canadian dollar held most of its gains against the US dollar on Monday, as hawkish remarks from Bank of Canada Governor Tiff Macklem drew more attention than domestic inflation data. The loonie traded 0.3% higher at 1.4095 per US dollar, near its strongest intraday level since September 23. Macklem said the BoC expects to raise its quarterly inflation forecast significantly this month because of persistently high oil and petroleum prices. Swap market data showed about an 80% chance of a BoC rate hike on October 28, up from 30% on Friday, while the benchmark rate has stayed at 2.25% since last October. Canadian bond yields rose across the curve, with the 10-year up 11.1 basis points to 3.940%, as investors also awaited a nonbinding Alberta referendum on secession.
- Homebuilder Sentiment Drops To Lowest Level Since 2012
Builder confidence has fallen to its lowest level since 2012, according to the NAHB and Wells Fargo Housing Market Index. Rising mortgage rates and higher energy and material costs have pushed sentiment to a 14-year low, keeping many buyers on the sidelines. The headline index rose one point to 38, still well below the breakeven level of 50, with affordability cited as a top concern for both buyers and builders. Builders also face elevated land, labor and construction costs, while NAHB Chief Economist Robert Dietz pointed to global events and energy prices as headwinds. He said efforts to ease regulatory burdens could still help improve long-term housing supply.
Get the briefing on Telegram or Zalo
Join the Upside Telegram channel or Zalo group for the Vietnam stocks and gold briefing at 8:00 and 19:00 (Vietnam time) on trading days, plus a weekly wrap on Saturday morning.